Brought to you by

Grace, Oxford Bioscience create gene delivery JV, Geniva
24 Oct 2019
Executive Summary
WR Grace put its Auragen genetic vaccine subsidiary--the remaining assets of its former Agracetus subsidiary--into Geniva, a 50-50 joint venture with Oxford Bioscience (drug delivery devices).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Joint Venture
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com